The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.
Daruka Mahadevan
Research Funding - Astex Therapeutics
Diane M Rensvold
No relevant relationships to disclose
Sandra E Kurtin
No relevant relationships to disclose
James M. Cleary
Research Funding - Astex Therapeutics
Leena Gandhi
Research Funding - Astex Therapeutics
John F. Lyons
Employment or Leadership Position - Astex Therapeutics
Stock Ownership - Astes Pharmaceuticals
Victoria Lock
Employment or Leadership Position - Astex Therapeutics
Stock Ownership - Astex Therapeutics
Samantha Lewis
Employment or Leadership Position - Astex Therapeutics
Stock Ownership - Astex Therapeutics
Geoffrey Shapiro
Research Funding - Astex Therapeutics